Wellell Gestione

Gestione criteri di controllo 1/4

We currently do not have sufficient information about the CEO.

Informazioni chiave

Daniel Lee

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	0.8%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	5.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Should You Or Shouldn't You: A Dividend Analysis on Apex Medical Corp. (TPE:4106)

Mar 29

Reflecting on Apex Medical's (TPE:4106) Share Price Returns Over The Last Five Years

Mar 01

Returns On Capital At Apex Medical (TPE:4106) Paint An Interesting Picture

Feb 11

Weak Financial Prospects Seem To Be Dragging Down Apex Medical Corp. (TPE:4106) Stock

Jan 27

Is Apex Medical (TPE:4106) Using Too Much Debt?

Jan 12

Is Apex Medical Corp. (TPE:4106) A Good Fit For Your Dividend Portfolio?

Dec 28

Does Apex Medical's (TPE:4106) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 13

Apex Medical (TPE:4106) Share Prices Have Dropped 28% In The Last Five Years

Nov 27

AMMINISTRATORE DELEGATO

Daniel Lee

no data

Mandato

Mr. Daniel Lee is Founder and CEO of Wellell Inc. He was President, GM & Chairman of Wellell Inc. from August 01, 2021. He was President & Chairman of Wellell Inc. until August 01, 2021. Mr. Lee was Sales...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Yong-Chuan Li	Chairman of the Board & GM	no data	Nessun dato	1.4% NT$ 35.7m
James Wang	Independent Director	5.4yrs	Nessun dato	Nessun dato
Wan Lin	Independent Director	11.4yrs	Nessun dato	Nessun dato
Yan Zhou	Supervisors	no data	Nessun dato	Nessun dato
Jin Li	Supervisor	no data	Nessun dato	Nessun dato
Der-Zen Liu	Representative Director	no data	Nessun dato	Nessun dato
Hsiung-Ching Lee	Independent Director	5.4yrs	Nessun dato	Nessun dato
Charles Liu	Director	no data	Nessun dato	Nessun dato
William Wang	Independent Director	no data	Nessun dato	Nessun dato
Peter Lin	Independent Director	no data	Nessun dato	Nessun dato

5.4yrs

Durata media

Consiglio di amministrazione esperto: 4106's board of directors are considered experienced (5.4 years average tenure).

Wellell Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Wellell Inc. Appoints Su Ya-Ling as Chief Operating Officer

Wellell Inc., Annual General Meeting, Jun 24, 2024

Wellell Inc. Appoints Lee Pi Kai as Chief Strategy Officer

Wellell Inc. Announces Resignation of Tan, Jian-Qiang as Chief Operating Officer

Wellell Inc. Appoints Shin-Ho,Chen as Corporate Governance Officer

Insufficient new directors

Recent updates

Wellell Inc. to Report Q3, 2024 Results on Nov 11, 2024

New minor risk - Profit margin trend

Second quarter 2024 earnings released: EPS: NT$0.21 (vs NT$0.50 in 2Q 2023)

Wellell Inc. to Report Q2, 2024 Results on Aug 13, 2024

Upcoming dividend of NT$0.80 per share

Wellell's (TWSE:4106) Dividend Is Being Reduced To NT$0.80

Wellell (TWSE:4106) Has Announced That Its Dividend Will Be Reduced To NT$0.80

Dividend reduced to NT$0.80

Wellell Inc. Approves Common Stock Cash Dividend, Payable on August 26, 2024

First quarter 2024 earnings released: EPS: NT$0.40 (vs NT$0.50 in 1Q 2023)

Wellell Inc. to Report Q1, 2024 Results on May 08, 2024

Wellell Inc. to Report Q1, 2024 Results on May 08, 2024

Some May Be Optimistic About Wellell's (TWSE:4106) Earnings

Wellell Inc. Appoints Su Ya-Ling as Chief Operating Officer

Full year 2023 earnings released: EPS: NT$1.51 (vs NT$1.60 in FY 2022)

Wellell Inc., Annual General Meeting, Jun 24, 2024

Wellell Inc. Appoints Lee Pi Kai as Chief Strategy Officer

Wellell Inc. Announces Resignation of Tan, Jian-Qiang as Chief Operating Officer

Second quarter 2023 earnings released: EPS: NT$0.50 (vs NT$0.51 in 2Q 2022)

Upcoming dividend of NT$0.85 per share at 2.7% yield

New minor risk - Dividend sustainability

Investor sentiment improves as stock rises 16%

Wellell Inc. Appoints Shin-Ho,Chen as Corporate Governance Officer

Full year 2022 earnings released: EPS: NT$1.60 (vs NT$1.01 in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: NT$0.59 (vs NT$0.31 in 3Q 2021)

Insufficient new directors

Wellell Inc. Announces Change Member of Remuneration Committee

Second quarter 2022 earnings released: EPS: NT$0.51 (vs NT$0.34 in 2Q 2021)

Insufficient new directors

Apex Medical Corp. Approves Cash Dividend for the Year 2021

Apex Medical Corp. Announces Change of Alan Chang as Research and Development Officer, Effective May 31, 2022

Apex (Kunshan)Medical Corp. to Announce Production Can Be Resume Gradually

Apex Medical Corp. Announces On Behalf of the Subsidiaries Apex (Kunshan) Medical Corp. and Wellell (Kunshan) Co., Ltd. Extend Temporary Suspension of Production

Wellell (Kunshan) Co., Ltd. Announces the Temporary Suspension of Production

Full year 2021 earnings released: EPS: NT$1.01 (vs NT$1.04 in FY 2020)

Wellell Inc., Annual General Meeting, Jun 20, 2022

Third quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.28 in 3Q 2020)

High number of new directors

High number of new directors

High number of new directors

Upcoming dividend of NT$0.55 per share

Second quarter 2021 earnings released: EPS NT$0.34 (vs NT$0.55 in 2Q 2020)

High number of new directors

High number of new directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$0.29 (vs NT$0.074 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS NT$1.04 (vs NT$0.87 in FY 2019)

Should You Or Shouldn't You: A Dividend Analysis on Apex Medical Corp. (TPE:4106)

Reflecting on Apex Medical's (TPE:4106) Share Price Returns Over The Last Five Years

Apex Medical Corp. Announces Executive Changes, Effective March 01, 2021

Returns On Capital At Apex Medical (TPE:4106) Paint An Interesting Picture

Apex Medical Corp. Appoints Alan Chang as Director of R&D

New 90-day low: NT$25.65

Weak Financial Prospects Seem To Be Dragging Down Apex Medical Corp. (TPE:4106) Stock

Is Apex Medical (TPE:4106) Using Too Much Debt?

New 90-day low: NT$28.00

Is Apex Medical Corp. (TPE:4106) A Good Fit For Your Dividend Portfolio?

Does Apex Medical's (TPE:4106) Statutory Profit Adequately Reflect Its Underlying Profit?

New 90-day low: NT$28.90

Apex Medical (TPE:4106) Share Prices Have Dropped 28% In The Last Five Years

Third quarter 2020 earnings released: EPS NT$0.28

New 90-day low: NT$31.05

First half earnings released

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione